Gilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion.
Latest posts by Market Watch (see all)
The Wall Street Journal: Gilead near deal to buy Immunomedics for more than $20 billion
